Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954286 · ClinicalTrials.gov registry record · Phase 2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
A Phase 2 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT05954286 is a Phase 2 study that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 92 participants.
The verdict
NCT05954286, a Phase 2 study, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Interventions
- DRUG Upamostat
- DRUG Placebo (PO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2025-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05954286
The ClinicalTrials.gov registry entry for NCT05954286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upamostat is the first listed.
NCT05954286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05954286 about?
NCT05954286 is a clinical study titled "PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19". This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
What is the current status of trial NCT05954286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2024-01-29. Estimated completion is 2025-04-24.
What interventions are being tested in trial NCT05954286?
The interventions under investigation include: Upamostat (DRUG), Placebo (PO) (DRUG).
Who is sponsoring clinical trial NCT05954286?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.